This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Immunization  • Hypertension  • Alert me on articles by topic

Mike Mitka

JAMA. 2007;298(24):2854-2855.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Orlando, Fla—Some patients with hypertension have inadequate control of blood pressure because they are not consistently adherent in taking their medications. But help may be on the way in the form of a vaccine that lowers blood pressure by controlling angiotensin II, suggest findings from a small safety study presented at the Scientific Sessions of the American Heart Association in November.

The study of 72 patients with mild-to-moderate hypertension, presented by Jürg Nussberger, MD, professor of medicine at the University Hospital of the Canton of Vaud, Lausanne, Switzerland, found that at 14 weeks, those injected with CYT006-AngQb (at 0, 4, and 12 weeks) had a daytime systolic blood pressure that was 5.6 mm Hg lower and a diastolic blood pressure 2.8 mm Hg lower than those of patients who received placebo.

CYT006-AngQb, which is under development by Cytos Biotechnology AG (Zurich, Switzerland), is a virus-shaped noninfectious particle . . . [Full Text of this Article]